How Transcription Factor 4 helps blood-vessel cells protect the heart

Transcription Factor 4 Maintain Endothelial identity to Oppose Heart Failure

NIH-funded research Boston Children's Hospital · NIH-11234265

This project sees if boosting a gene called Transcription Factor 4 in blood-vessel (endothelial) cells can reduce scarring and help people with heart failure.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionBoston Children's Hospital NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-11234265 on NIH RePORTER

What this research studies

From a patient's perspective, researchers are studying how a gene called Transcription Factor 4 (TF4) keeps heart blood-vessel cells working properly and how loss of that function may drive scarring in heart failure. They will use lab-grown human cells, genetic lineage tracing in animal models, and computational analysis of gene and epigenetic patterns to map how endothelial cells communicate with fibroblasts. The team will test whether restoring TF4-related programs reduces fibroblast activation and heart fibrosis in experimental models. The goal is to identify pathways or targets that could lead to new treatments to protect blood vessels and limit heart stiffening and symptoms.

Who could benefit from this research

Good fit: People with heart failure—especially those with signs of endothelial dysfunction or cardiac fibrosis—would be most relevant for sample donation or future related clinical work.

Not a fit: People without heart failure or whose heart problems are driven by non-fibrotic causes are unlikely to see direct benefit from this specific line of research.

Why it matters

Potential benefit: If successful, this work could point to new therapies that protect blood-vessel cells, reduce cardiac scarring, and improve function and symptoms in people with heart failure.

How similar studies have performed: Related research mapping endothelial signaling and targeting fibrosis has shown promise in preclinical models, but targeting TF4 specifically is a newer and less-tested approach.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.